Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kodiak Sciences Inc KOD

Healthcare Biotechnology
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti... see more

Recent & Breaking News (NDAQ:KOD)

Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

PR Newswire February 23, 2022

Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema

PR Newswire February 3, 2022

Kodiak Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

PR Newswire January 3, 2022

Kodiak Sciences Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion

PR Newswire December 16, 2021

Kodiak Sciences Announces Third Quarter 2021 Financial Results and Recent Business Highlights

PR Newswire November 9, 2021

Kodiak Sciences to Present at Upcoming Conferences

PR Newswire November 8, 2021

Kodiak Sciences Announces New Long-Term Performance Incentive Plan

PR Newswire September 1, 2021

Kodiak Sciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

PR Newswire August 31, 2021

Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights

PR Newswire August 9, 2021

Kodiak Sciences to Present at Upcoming Conferences

PR Newswire May 20, 2021

Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Kodiak Sciences Inc. (NASDAQ: KOD) Investors

GlobeNewswire May 19, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Kodiak Sciences Inc. - KOD

PR Newswire May 18, 2021

Kodiak Sciences Announces First Quarter 2021 Financial Results and Recent Business Highlights

PR Newswire May 10, 2021

Kodiak Sciences to Present at Upcoming Conferences

PR Newswire April 21, 2021

Kodiak Sciences to Present at Upcoming Conferences

PR Newswire March 2, 2021

Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

PR Newswire March 1, 2021

Kodiak Sciences Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting

PR Newswire February 13, 2021

Kodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition

PR Newswire February 2, 2021

Kodiak Sciences to Present at the J.P. Morgan Healthcare Conference

PR Newswire January 5, 2021

Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

PR Newswire November 20, 2020